Dyne Therapeutics reports Q1 EPS (81c), consensus (80c)

Cash, cash equivalents and marketable securities were $453.5M as of March 31. In addition, subsequent to March 31, 2023, the company received $24.3M from the sale of stock through its “at the market” offering program. The company’s cash, cash equivalents and marketable securities are anticipated to fund operations through 2025. “I am excited about the opportunity that Dyne, its FORCE platform and pipeline present for individuals living with serious muscle diseases,” said John Cox, president and CEO of Dyne. “The initial datasets announced in January from our DM1 and DMD programs were promising, and we look forward to reporting additional data from multiple, higher dose cohorts from the ACHIEVE and DELIVER trials during the second half of 2024. With a strong team and cash position, we are focused on executing across the business, including progressing towards initiating registrational cohorts in both trials by year-end.”